ArticleInternational journal of clinical and experimental pathology2017
CKIP-1 serves as a negative regulator and correlates with the degree of differentiation in gastric cancer.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- CKIP-1 inhibits M2 macrophage polarization to suppress the progression of gastric cancer by inactivating JAK/STAT3 signaling.Cell biochemistry and biophysics · 2025Article
- CKIP-1 silencing suppresses OSCC via mitochondrial homeostasis-associated TFAM/cGAS-STING signalling axis.Journal of cellular and molecular medicine · 2024Article
- High expression of theThe Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most commonly diagnosed malignancies worldwide. CKIP-1 is a casein kinase-2 α-subunit (CK2α) interacting protein. Though previous reports have shown that CKIP-1 plays a critical role in several types of cancers, hardly there are any studies that examined the role of CKIP-1 in the progression of GC. Our present study aimed to investigate the role of CKIP-1 in GC. Results demonstrated low-level expression of CKIP-1 in GC tissues and cell lines. Moreover, knockdown of CKIP-1 promoted cell proliferation, migration, and invasion in GC cell lines, whereas CKIP-1 overexpression inhibited proliferation, migration, and invasion in the cells. Altogether, our data suggests that CKIP-1 may act as a novel tumor suppressor gene in GC and is related to GC differentiation.
Indexed as
Identifiers
31966411PMC6965809W2767553270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.